Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering from What is Known As Long COVID (LC)

Recruiting

Phase 2

Xiflam™Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering from What is Known As Long COVID (LC)

Sponsor:

Inflammx Therapeutics Inc

Code:

NCT06437223

Conditions

Long COVID

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Tonabersat

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-25. This information was provided to ClinicalTrials.gov by Inflammx Therapeutics Inc on 2025-02-25.